← FDA DRUG APPROVALS

FDA ANDA · ANDA078499

TOPIRAMATE

Sponsor: AIPING PHARM INC

APPLICATION
ANDA078499
TYPE
ANDA
ORIGINAL APPROVAL
2010-01-07
LATEST ACTION
2026-06-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TOPIRAMATEDiscontinued
TOPIRAMATE 100MG · TABLET · ORAL
TOPIRAMATEDiscontinued
TOPIRAMATE 25MG · TABLET · ORAL
TOPIRAMATEDiscontinued
TOPIRAMATE 200MG · TABLET · ORAL
TOPIRAMATEDiscontinued
TOPIRAMATE 50MG · TABLET · ORAL

Approval history

2026-06-15Labeling · Supplement 9 · standardAP
2014-11-19Labeling · Supplement 8 · standardAP
2014-11-19Labeling · Supplement 7 · standardAP
2011-06-17Labeling · Supplement 6AP
2011-06-17Labeling · Supplement 4AP
2010-08-17Labeling · Supplement 3AP
2010-01-07OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →